The Unprecedented Rise in Medicaid’s Diabetes Drug Spending
Introduction to the Crisis
Medicaid faces a staggering projection of $29.9 billion in expenditure for type 2 diabetes and weight loss medications, according to a recent report from…
Women’s telehealth company Wisp announced a strategic partnership with food as medicine platform Nourish to allow Wisp patients to access nutrition counseling services via their health insurance or an exclusive self-pay rate The aim is…
Continue Reading
Women’s telehealth company Wisp and food as medicine platform Nourish have launched a partnership to support patients taking GLP-1s, the companies announced Wednesday. Wisp patients can now access nutrition counseling support through Nourish.
New York…
Continue Reading
What You Should Know:
– A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with…
Continue Reading
As the nation grapples with a GLP-1 shortage, Hims & Hers is looking to improve access by making compounded GLP-1s available on its platform starting at $199 a month, the company announced Monday.
The San…
Continue Reading
Direct-to-consumer virtual care company Hims & Hers is the latest digital health company to announce it will add GLP-1 medications to its offerings to assist users with weight loss management. The San Francisco-based company, which…
Continue Reading
Guy Friedman, co-founder and CEO of SteadyMD
The past few years have seen upheavals in healthcare, and 2024 so far shows no signs of breaking that pattern.
While the fundamentals of healthcare remain the same –…
Continue Reading
GLP-1 medications like Ozempic and Wegovy remain in high demand and continue to make headlines, even among mainstream media outlets. As the healthcare industry watches closely to see how payers decide to cover the…
Continue Reading
GLP-1 medications like Ozempic, Wegovy, and Mounjaro have ushered in a new era for the weight loss market in 2024 and surfaced several questions that have been festering for quite some time and can…
Continue Reading
News and social media are saturated with articles about the demand for and shortage of glucagon-like peptide-1 (GLP-1) drugs marketed for weight loss. The best-known of these drugs is semaglutide, sold under the brand…
Continue Reading
